Skip to main content
    V

    Verastem Inc (VSTM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.70
    -0.48 (-5.87%)

    Market Cap: $1.03B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Verastem Inc (VSTM) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Verastem (VSTM) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, Verastem reported EPS of -$0.74, below the -$0.44 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    40%(16/40)
    Avg Surprise
    -7.71%

    Upcoming Estimates

    Reports Mar 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.50
    Range-$0.70 - -$0.36
    12 analysts
    Revenue Consensus
    $27.36M
    Range$24.60M - $30.26M
    11 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.43
    Range-$0.43 - -$0.43
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current-$0.43
    Revenue Consensus
    $27.63M
    Range$24.50M - $30.49M
    3 analysts

    Next Report

    VSTM has an expected report date of Mar 2, 2027.

    VSTM Earnings Call

    The latest VSTM earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, VSTM beat 16, missed 22 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $24.01M, up 113.6% from $11.24M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.74-$0.44-$0.44 - -$0.44-68.18%MissN/A20 up, 1 downNov 5, 2026$24.01M
    Jun 30, 2026-$0.35-$0.46N/A+23.91%BeatN/A31 up, 0 downAug 6, 2026$40.08M
    Mar 31, 2026-$0.43-$0.47-$0.50 - -$0.44+8.51%BeatN/A31 up, 0 downMay 7, 2026$18.67M
    Dec 31, 2025-$0.46-$0.50-$0.51 - -$0.47+7.55%BeatN/A31 up, 0 downMar 4, 2026$17.54M
    Sep 30, 2025-$0.54-$0.61-$0.68 - -$0.56+11.48%BeatN/A31 up, 0 downNov 4, 2025$11.24M
    Jun 30, 2025-$0.39-$0.59N/A+33.90%BeatN/A2N/AAug 7, 2025$2.14M
    Mar 31, 2025-$0.79-$0.77-$0.94 - -$0.61-2.60%MissN/A21 up, 0 downMay 13, 2025N/A
    Dec 31, 2024-$0.60-$0.74-$0.92 - -$0.53+18.56%BeatN/A30 up, 1 downMar 20, 2025N/A
    Sep 30, 2024-$0.88-$0.82-$1.08 - -$0.65-7.32%MissN/A90 up, 0 downNov 6, 2024N/A
    Jun 30, 2024-$0.61-$1.06-$1.11 - -$0.65+42.45%BeatN/A71 up, 0 downAug 8, 2024$10.00M
    Mar 31, 2024-$0.98-$0.87-$1.19 - -$0.87-12.64%MissN/A50 up, 0 downMay 9, 2024N/A
    Dec 31, 2023-$1.02-$0.62-$0.88 - $0.43-64.52%MissN/A70 up, 0 downMar 14, 2024$114000
    Sep 30, 2023-$0.71-$0.79-$1.22 - -$0.74+10.13%BeatN/A70 up, 0 downNov 8, 2023N/A
    Jun 30, 2023-$1.15-$1.02-$1.20 - -$0.83-12.75%MissN/A52 up, 0 downAug 8, 2023N/A
    Mar 31, 2023-$1.14-$0.98-$1.08 - -$0.84-16.33%MissN/A50 up, 0 downMay 9, 2023N/A
    Dec 31, 2022-$0.08-$0.10-$0.10 - -$0.09+20.00%BeatN/A50 up, 0 downMar 14, 2023$2.60M
    Sep 30, 2022-$1.08-$1.47-$1.56 - -$1.44+26.53%BeatN/A60 up, 0 downNov 3, 2022N/A
    Jun 30, 2022-$1.44-$1.32N/A-9.09%MissN/AN/A0 up, 0 downAug 8, 2022N/A
    Mar 31, 2022-$1.08-$1.02-$1.20 - -$0.84-5.88%MissN/A50 up, 1 downMay 9, 2022$2.60M
    Dec 31, 2021-$0.09-$0.09-$0.12 - -$0.080.00%In lineN/A4N/AMar 28, 2022$1.55M
    Sep 30, 2021-$1.56-$0.84-$1.08 - -$0.84-85.71%Miss-262.5%4N/ANov 4, 2021$2000
    Jun 30, 2021-$1.20-$1.00-$1.08 - -$0.96-20.00%MissN/A3N/AAug 2, 2021$500000
    Mar 31, 2021-$1.08-$1.08-$1.08 - -$1.080.00%In lineN/A1N/AMay 11, 2021N/A
    Dec 31, 2020-$0.12-$0.08-$0.11 - -$0.06-50.00%MissN/A2N/AMar 18, 2021$506000
    Sep 30, 2020$0.96$0.52-$0.96 - $3.36+84.62%BeatN/A3N/ANov 9, 2020$78.65M
    Jun 30, 2020-$1.68-$1.76-$2.16 - -$1.32+4.55%BeatN/A3N/AAug 10, 2020$4.31M
    Mar 31, 2020-$4.20-$2.58-$3.36 - -$2.16-62.79%MissN/A4N/AMay 7, 2020$5.06M
    Dec 31, 2019-$0.51-$0.45-$0.65 - -$0.33-13.33%MissN/A4N/AMar 11, 2020$3.62M
    Sep 30, 2019-$4.20-$4.92-$6.36 - -$4.92+14.63%BeatN/A4N/AOct 29, 2019$9.03M
    Jun 30, 2019-$5.76-$5.84-$6.72 - -$5.76+1.37%BeatN/A5N/AAug 1, 2019$3.14M
    Mar 31, 2019-$6.24-$5.64-$6.00 - -$5.04-10.64%MissN/A6N/AMay 9, 2019$1.67M
    Dec 31, 2018-$0.49-$0.53-$0.79 - -$0.34+7.55%BeatN/A6N/AMar 12, 2019$1.21M
    Sep 30, 2018-$5.97-$4.68-$6.12 - -$4.68-27.56%MissN/A7N/ANov 7, 2018$15.51M
    Jun 30, 2018-$5.56-$4.30-$4.80 - -$2.64-29.30%MissN/A8N/AAug 8, 2018$10.00M
    Mar 31, 2018-$0.41-$0.39-$0.50 - -$0.36-5.13%MissN/A6N/AMay 3, 2018N/A
    Dec 31, 2017-$5.16-$5.10-$6.72 - -$4.08-1.18%MissN/A6N/AMar 13, 2018N/A
    Sep 30, 2017-$7.32-$3.96N/A-84.85%MissN/AN/AN/ANov 7, 2017N/A
    Jun 30, 2017-$4.32-$3.96N/A-9.09%MissN/AN/AN/AAug 8, 2017N/A
    Mar 31, 2017-$4.20-$4.32N/A+2.78%BeatN/AN/AN/AMay 10, 2017N/A
    Dec 31, 2016-$0.32-$0.25N/A-28.00%MissN/AN/AN/AMar 23, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.18, after -$3.07 the year before. It was -$5.82 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.18N/A
    Dec 31, 2024-$3.07N/A
    Dec 31, 2023-$4.02N/A
    Dec 31, 2022-$3.68N/A
    Dec 31, 2021-$3.93N/A
    Dec 31, 2020-$5.04N/A
    Dec 31, 2019-$16.71N/A
    Dec 31, 2018-$12.43N/A
    Dec 31, 2017-$21.00N/A
    Dec 31, 2016-$5.82N/A

    Earnings Calls

    The 6 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,70315
    2026Q2Jun 30, 20265,21014
    2026Q1Mar 31, 20267,98114
    2025Q4Dec 31, 20257,12213
    2025Q3Sep 30, 20254,83512
    2025Q2Jun 30, 20256,47115

    2026Q3 Earnings Call

    Opening remarks

    Julissa Viana Senior Vice President of Corporate Communications, Investor Relations and Patient Advocacy Thank you, operator. Welcome, everyone, and thank you for joining us today to discuss Verastem's Third Quarter 2026 financial results and recent business updates. This afternoon, we issued a press release detailing these results, along with the slide presentation that we will reference during our call today. Both are available on the Investor Relations section of our website. Before we begin, let me point out that we'll be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Additionally, today, we'll be discussing certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are provided in the press release we issued today. Joining me on today's call to deliver prepared remarks and take your questions are Dan Paterson, President and Chief Executive Officer; Dan Lyons, Chief Commercial Officer; Dr. Michael D. Kauffman, President of Development; and lastly, Dan Calkins, Chief Financial Officer. I will now turn the call over to Dan.

    Daniel Paterson President and Chief Executive Officer Thank you, Julissa. Good afternoon, and thank you for joining our call today. We're encouraged by the progress we've made across our commercial business and the VS-7375 development program. We generated net product revenue of $24 million in the third quarter, with demand holding steady for AVMAPKI FAKZYNJA CO-PACK and strong refills offsetting new patient starts after significant growth in Q2. As Dan Lyons will discuss, we feel that there's still considerable opportunity to be realized for the CO-PACK. While we continue to see a positive impact from the changes we've made throughout the commercial organization, we're making additional efforts to gather feedback from physicians to understand patient experiences and educate on new and existing initiatives. We're also excited to share that our new blister pack NDA has been accepted by the FDA with priority review and a PDUFA date of February 2027. This is an important step we are taking to further support patient convenience and adherence to the CO-PACK. Turning to the VS-7375 program. In October, we announced new clinical data from our TARGET-D 101 trial, including, for the first time, U.S. efficacy data and updated safety and tolerability results in KRAS G12D-mutated pancreatic, colorectal and lung cancers. As Michael Kauffman will discuss in more detail, we set a new efficacy benchmark in pancreatic cancer with compelling and confirmed response rates across lines of therapy, and we demonstrated encouraging antitumor activity in both colorectal and non-small cell lung cancers. With longer follow-up, VS-7375 continued to demonstrate a favorable and manageable safety profile at both the 600- and 900-milligram dose levels.

    Frequently Asked Questions About VSTM

    When is Verastem's next earnings date?

    Verastem's next earnings report is expected for Mar 2, 2027.

    Did VSTM beat earnings estimates last quarter?

    No. Verastem reported EPS of -$0.74 for the quarter ended Sep 30, 2026, below the -$0.44 estimate by 68.18%.

    What EPS do analysts expect from VSTM next quarter?

    The consensus EPS estimate for Verastem for the quarter ending Dec 31, 2026 is -$0.50 from 12 analysts, with estimates from -$0.70 to -$0.36.

    How often does VSTM beat earnings estimates?

    Verastem beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +4.14%.